title: Symptomatic ICH and outcomes in patients after IV tPA: a business of risk or risky business?
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Southerland
authors.forename: Shaneela
authors.initials: S
authors.lastname: Malik
authors.forename: Karen C
authors.initials: KC
authors.lastname: Johnston
mesh_terms: D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D012307:Risk Factors; D020521:Stroke / Q000150:complications / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator